Posted by Michael Wonder on 13 Oct 2023
Astellas receives positive CHMP opinion for Veoza (fezolinetant)
13 October 2023 - Fezolinetant is an investigational non-hormonal treatment for vasomotor symptoms associated with menopause.
Astellas today announced the CHMP of the EMA on October 12 adopted a positive opinion relating to the use of Veoza (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms associated with menopause.
